+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of trastuzumab deruxtecan T-DXd combined with rilvegostomig, and T-DXd alone, compared with the standard treatment of gemcitabine, cisplatin, and durvalumab for patients with advanced, untreated HER2-expressing biliary tract cancer. This Phase 3 study focuses on patients with locally advanced or metastatic disease, aiming to compare overall survival and other outcomes across different treatment groups. Participants are assigned to one of three groups one receiving T-DXd and rilvegostomig together, another receiving T-DXd alone, and a third receiving the standard care of gemcitabine, cisplatin, and durvalumab. All treatments are given by intravenous infusion. The study includes an initial safety run-in phase followed by a randomized portion where patients receive assigned treatments until disease progression or other criteria are met. The study is estimated to continue for up to 50 months after the first patient is randomized. During the trial, participants will have tumor samples collected, and their disease will be monitored through imaging and clinical assessments. Researchers will evaluate safety, tolerability, overall survival, progression-free survival, response rates, and patient-reported outcomes like side effects and physical functioning. Blood samples will be taken to study drug levels and immune responses. The study plans to follow participants for long-term outcomes and side effects, with regular visits scheduled throughout the study duration.

Age: 18Years - 99YearsAll GendersPhase 3
272 locations